A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients With Primary Hyperoxaluria Type 3
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Nedosiran (Primary)
- Indications Primary hyperoxaluria
- Focus Adverse reactions
- Acronyms PHYOX4
- Sponsors Dicerna Pharmaceuticals
- 19 Oct 2021 Top-line results published in the Dicerna Pharmaceuticals Media Release.
- 09 Sep 2021 Status changed from active, no longer recruiting to completed.
- 10 Aug 2021 Planned End Date changed from 8 Jul 2021 to 7 Sep 2021.